04Feb 2018

FIXED-DOSE IRBESARTAN-HYDROCHLOROTHIAZIDE TREATMENT ADHERENCE IN ESSENTIAL HYPERTENSION PATIENTS: REGIONAL, MULTICENTER, NON-INTERVENTIONAL, NON-CONTROLLED, 3 MONTHS COHORT STUDY, PROSPECTIVE REGISTRY IN THE GULF REGION.

  • American Hospital, Dubai, UAE.
  • Shatti Qurum Medical centre. Shatti Al Qurum, Muscat, Oman.
  • Rumaitheya Polyclinic, Kuwait.
  • Royal Bahrain Hospital, Bahrain.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Hypertension persists as a major public health challenge worldwide and is predominantly caused by treatment non-adherence. Assessments of adherence and barriers to antihypertensive therapies in the Gulf region are needed. We aim to assess adherence to ? and the tolerability, safety, and efficacy of ? fixed-dose irbesartan-hydrochlorothiazide in hypertensive patients across several countries in the Gulf region. Essential hypertension patients for whom fixed-dose irbesartan-hydrochlorothiazide was prescribed at physicians? discretion were followed for three months. Treatment adherence (using The Morisky Medication Adherence Scale (MMAS-8)), tolerability, safety, and efficacy were assessed throughout the study period. Barriers preventing treatment adherence were also identified. We found that 70.9% of patients (n=681) were adherent to fixed-dose irbesartan-hydrochlorothiazide therapy following three months of treatment. An adverse event rate of 0.4% (n=4) was reported; 0.1% (n=1) of patients experienced serious adverse events. Following three months of treatment, 73.3% of patients (n=704) reached their target Blood Pressure (BP). Achievement of target BP was more prevalent in non-diabetic hypertensive patients (75.5% vs. 69.1%; p=0.033). Inconvenience of daily treatment was the most commonly reported barrier to adherence; 60.4% (n=169). In conclusion, Fixed-dose irbesartan-hydrochlorothiazide treatments can aid patients ? including diabetics ? correct elevated BP. High tolerability andtreatment effectiveness and a convenient dosing schedule are likely contributors to high antihypertensive treatment adherence.

  1. Al-Qasem A, Smith F, Clifford S. Adherence to medication among chronic patients in Middle Eastern countries: review of studies. Eastern Mediterranean Health Journal. 2011 Apr 1; 17(4).
  2. American Diabetes Association. Position statement: Treatment of hypertension in adults with diabetes. Diabetes Care. 2002 Jan 1; 25(1):199.
  3. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. The American journal of medicine. 2007 Aug 31; 120(8):713-9.
  4. Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N, Asmar R. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. American journal of hypertension. 2005 Nov 1; 18(11):1482-8.
  5. Bramlage P. Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension. Vasc Health Risk Manag. 2009 Jan 1; 5(1):213-4.
  6. Breaux-Shropshire TL, Brown KC, Pryor ER, Maples EH. Relationship of blood pressure self-monitoring, medication adherence, self-efficacy, stage of change, and blood pressure control among municipal workers with hypertension. Workplace health & safety. 2012 Jul; 60(7):303-11.
  7. Burnier M, Hess B, Greminger P, Waeber B. Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey. BMC cardiovascular disorders. 2005 Jun 8; 5(1):13.
  8. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. Canadian Medical Association Journal. 1999 Jan 12;160(1):31-7.
  9. Coca A, Calvo C, Sobrino J, L?pez-Paz J, Sierra C, G?mez E, Bragulat E, de la Sierra Once-daily fixed-combination irbesartan 300 mg/hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. Clinical therapeutics. 2003 Nov 1; 25(11):2849-64.
  10. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. British medical bulletin. 1994 Jan 1; 50(2):272-98.
  11. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, Merlino L, Mancia G. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. Journal of hypertension. 2010 Jul 1; 28(7):1584-90.
  12. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly. American journal of cardiovascular drugs. 2008 Jan 1; 8(1):45-50.
  13. Domino FJ. Improving adherence to treatment for hypertension. American family physician. 2005 Jun 1; 71(11).
  14. Gehani AA, Al-Hinai AT, Zubaid M, Almahmeed W, Hasani MM, Yusufali AH, Hassan MO, Lewis BS, Islam S, Rangarajan S, Yusuf S. Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study. European journal of preventive cardiology. 2014 Apr 1; 21(4):400-10.
  15. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence. Circulation. 2009 Jun 16; 119(23):3028-35.
  16. Khalil SA, Elzubier AG. Drug compliance among hypertensive patients in Tabuk, Saudi Arabia. Journal of hypertension. 1997 May 1; 15(5):561-5
  17. Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. American journal of hypertension. 1999 Aug 31; 12(8):797-805
  18. Krousel-Wood MA, Muntner P, Islam T, Morisky DE, Webber LS. Barriers to and determinants of medication adherence in hypertension management: perspective of the cohort study of medication adherence among older adults. Medical Clinics of North America. 2009 May 31; 93(3):753-69.
  19. Leon K, Tawfik M, Gamal A, Zidan A. Observational study on patients? compliance with Irbesartan in essential hypertension ?I Comply?. The Egyptian Heart Journal. 2014 Mar 31; 66(1):35-42.
  20. Majernick TG, Zacker C, Madden NA, Belletti DA, Arcona S. Correlates of hypertension control in a primary care setting. American journal of hypertension. 2004 Oct 31; 17(10):915-20.
  21. Mallat SG, Samra SA, Younes F, Sawaya MT. Identifying predictors of blood pressure control in the Lebanese population-a national, multicentric survey?I-PREDICT. BMC public health. 2014 Nov 5; 14(1):1142.Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, B?hm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood pressure. 2013 Aug 1; 22(4):193-278.
  22. Myat A, Redwood SR, Qureshi AC, Spertus JA, Williams B. Resistant hypertension. Bmj. 2012 Nov 20; 345:e7473.
  23. Mohd MM, Phung H, Sun J, Morisky DE. Improving adherence to medication in adults with diabetes in the United Arab Emirates. BMC Public Health. 2016 Aug 24; 16(1):857.
  24. Morisky DE, Ang A, Krousel‐Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. The Journal of Clinical Hypertension. 2008 May 1; 10(5):348-54.
  25. Neutel JM, Franklin SS, Bhaumik A, Lapuerta P, Oparil S. Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension. Clinical and Experimental Hypertension. 2009 Nov 1; 31(7):572-84.
  26. Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptaszynska A, Lapuerta P. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. The Journal of Clinical Hypertension. 2006 Dec 1; 8(12):850-9.
  27. Rochlani Y, Khan MH, Banach M, Aronow WS. Are two drugs better than one? A review of combination therapies for hypertension. Expert Opinion on Pharmacotherapy. 2017 Jan 30(just-accepted).
  28. Shelley D, Tseng TY, Andrews H, Ravenell J, Wu D, Ferrari P, Cohen A, Millery M, Kopal H. Predictors of blood pressure control among hypertensives in community health centers. American journal of hypertension. 2011 Dec 1; 24(12):1318-23.
  29. Sowers JR, Haffner S. Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension. 2002 Dec 1; 40(6):781-8.
  30. Sowers JR. Treatment of hypertension in patients with diabetes. Archives of internal medicine. 2004 Sep 27; 164(17):1850-7.
  31. Tailakh A, Evangelista LS, Mentes JC, Pike NA, Phillips LR, Morisky DE. Hypertension prevalence, awareness, and control in Arab countries: a systematic review. Nursing & health sciences. 2014 Mar 1; 16(1):126-30.
  32. US Food and Drug Administration. Highlights of prescribing information. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020758s058lbl.pdf [accessed 2017-03-26]
  33. Weir MR, Neutel JM, Bhaumik A, Obaldia ME, Lapuerta P. The Efficacy and Safety of Initial Use of Irbesartan/Hydrochlorothiazide Fixed‐Dose Combination in Hypertensive Patients With and Without High Cardiovascular Risk. The Journal of Clinical Hypertension. 2007 Dec 1; 9(s12):23-30.
  34. World Health Organization. A global brief on hypertension: Silent killer, global public health crisis. URL: http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf?ua=1 [accessed 2017-03-26].
  35. Zannad F. Practical relevance of the 24 hours trough: peak ratio of antihypertensive drugs. Journal of Hypertension. 1995 Aug 1; 13:S109-12.

[Omar Al Hallaq, Mustafa al abousi, Nabeel Abd Al Hameed and Waleed Sultan. (2018); FIXED-DOSE IRBESARTAN-HYDROCHLOROTHIAZIDE TREATMENT ADHERENCE IN ESSENTIAL HYPERTENSION PATIENTS: REGIONAL, MULTICENTER, NON-INTERVENTIONAL, NON-CONTROLLED, 3 MONTHS COHORT STUDY, PROSPECTIVE REGISTRY IN THE GULF REGION. Int. J. of Adv. Res. 6 (Feb). 427-437] (ISSN 2320-5407). www.journalijar.com

Omar al Hallaq
Consultant Interventional Cardiologist, American Hospital, Dubai

DOI:

Article DOI: 10.21474/IJAR01/6454      
DOI URL: https://dx.doi.org/10.21474/IJAR01/6454

Download Full Paper

Download PDF No. of Downloads: 10 | No. of Views: 102